Galectin Therapeutics Inc. (GALT) Financials

GALT Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 22.2 million 73.0 million
2023-06-30 20.1 million 71.2 million
2023-03-31 20.2 million 62.9 million
2022-12-31 21.3 million 53.5 million

GALT Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -7.6 million 586000
2023-06-30 -9.8 million 516000
2023-03-31 -10.8 million 662000
2022-12-31 -7.2 million 681000

GALT Net Income

No data available :(

GALT Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 20.4 million - 77000
2023-06-30 18.0 million - 43000
2023-03-31 17.8 million - 97000
2022-12-31 18.6 million - 40000

GALT Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 59.7 million
2023-06-30 59.6 million
2023-03-31 59.5 million
2022-12-31 59.4 million

GALT Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 - 7.7 million 1.4 million -
2023-06-30 - 7.4 million 1.6 million -
2023-03-31 - 8.8 million 1.5 million -
2022-12-31 - 9.0 million 1.6 million -

GALT Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 - 8000
2023-06-30 - -
2023-03-31 - 32000
2022-12-31 - 8000

GALT

Price: $3.37

52 week price:
1.28
4.27

Earnings Per Share: -0.74 USD

P/E Ratio: -2.28

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 205300

Ebitda: -4.4 million

Market Capitalization: 238.9 million

Links: